Zoetis Inc (ZTS)
194.81
-0.06
(-0.03%)
USD |
NYSE |
Sep 27, 16:00
194.91
+0.10
(+0.05%)
After-Hours: 20:00
Zoetis Research and Development Expense (TTM): 659.00M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 659.00M |
| March 31, 2024 | 634.00M |
| December 31, 2023 | 614.00M |
| September 30, 2023 | 588.00M |
| June 30, 2023 | 570.00M |
| March 31, 2023 | 559.00M |
| December 31, 2022 | 539.00M |
| September 30, 2022 | 529.00M |
| June 30, 2022 | 527.00M |
| March 31, 2022 | 512.00M |
| December 31, 2021 | 508.00M |
| September 30, 2021 | 503.00M |
| June 30, 2021 | 483.00M |
| March 31, 2021 | 474.00M |
| December 31, 2020 | 463.00M |
| September 30, 2020 | 462.00M |
| June 30, 2020 | 462.00M |
| March 31, 2020 | 462.00M |
| December 31, 2019 | 457.00M |
| September 30, 2019 | 450.00M |
| June 30, 2019 | 446.00M |
| March 31, 2019 | 437.00M |
| December 31, 2018 | 432.00M |
| September 30, 2018 | 417.00M |
| June 30, 2018 | 405.00M |
| Date | Value |
|---|---|
| March 31, 2018 | 389.00M |
| December 31, 2017 | 382.00M |
| September 30, 2017 | 380.00M |
| June 30, 2017 | 374.00M |
| March 31, 2017 | 376.00M |
| December 31, 2016 | 376.00M |
| September 30, 2016 | 377.00M |
| June 30, 2016 | 378.00M |
| March 31, 2016 | 374.00M |
| December 31, 2015 | 364.00M |
| September 30, 2015 | 379.00M |
| June 30, 2015 | 381.00M |
| March 31, 2015 | 389.00M |
| December 31, 2014 | 396.00M |
| September 30, 2014 | 393.00M |
| June 30, 2014 | 393.00M |
| March 31, 2014 | 396.00M |
| December 31, 2013 | 399.00M |
| September 30, 2013 | 399.00M |
| June 30, 2013 | 400.00M |
| March 31, 2013 | 397.00M |
| December 31, 2012 | 409.00M |
| September 30, 2012 | 407.00M |
| June 30, 2012 | 415.00M |
| March 31, 2012 | 428.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
450.00M
Minimum
Sep 2019
659.00M
Maximum
Jun 2024
522.75M
Average
510.00M
Median
Research and Development Expense (TTM) Benchmarks
| Pfizer Inc | 10.72B |
| Alnylam Pharmaceuticals Inc | 1.080B |
| Biomarin Pharmaceutical Inc | 786.34M |
| Corcept Therapeutics Inc | 217.47M |
| Ionis Pharmaceuticals Inc | 908.16M |